Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCV24 (low-dose 1)
- Development stage
- Unknown
- Lead developer
- Shanghai Reinovax Biologics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
PCV24 (low-dose 1) is a specific formulation of a 24-valent pneumococcal polysaccharide conjugate vaccine being developed by Shanghai Reinovax Biologics (also known as Shanghai Ruizhou Biotechnology) in collaboration with Changchun Ruizhou Biopharmaceutical. This formulation contains capsular polysaccharides from 24 Streptococcus pneumoniae serotypes (1, 2, 3, 4, 5, 6A, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F) conjugated to a carrier protein to enhance immunogenicity by inducing T-cell-dependent immune responses. Specifically, the 'low dose-1' version contains 4.0 μg of polysaccharide for serotypes 3, 6B, and 12F, and 2.0 μg for the remaining 21 serotypes, adsorbed on 0.125 mg of aluminum phosphate adjuvant. It is currently undergoing Phase 2 clinical evaluation in China for the prevention of pneumococcal disease in adults.
- Other names
- 24-valent pneumococcal polysaccharide conjugate vaccine (low-dose 1)Shanghai Ruizhou PCV24 (low-dose 1)Reinovax PCV24 (low-dose 1)
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on PCV24 (low-dose 1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCV24 (low-dose 1).